| Formulary Chapter 9: Nutrition and blood - Full Chapter
|
| 09.01.03 |
Drugs used in hypoplastic, haemolytic, and renal anaemias |
|
|
| 09.01.03 |
Erythropoietin |
|
|
Darbepoetin alfa
(Aranesp®)
|
 Restricted
 
|
Provider notes
- NMUH:
- For continuation of supply for those renal patients that have been initiated on treatment by Royal Free Hospital.
- RFL:
- Restricted to Renal team – preferred brand of erythropoietin
- Restricted to Haematology for MDS
- RNOH:
- UCLH:
- WH:
|
 NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
|
Epoetin alfa
(Eprex®)
|
Restricted
|
Provider notes
- NMUH:
- For anaemia associated with chronic renal failure only.
- Restricted to renal consultants signature and Dr. Tindall signature only.
- Please note that the CSM has advised that the subcutaneous route is contraindicated in chronic renal failure. Please use the IV route instead. The dialysis unit has changed over to NeoRecormon which is an IV preparation.
- RFL:
- Restricted to Renal team - for patients who cannot tolerate darbepoetin or established patients only
- RNOH:
- UCLH:
- WH:
- Epoetin is available for treatment anaemia of renal disease only
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
|
Epoetin beta
(NeoRecormon®)
|
Restricted
|
Provider notes
- NMUH:
- Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
- Restricted to Renal and Haematology Consultants.
- See MHRA drug safety updates
- RFL:
- Restricted to Renal team - for patients who cannot tolerate darbepoetin or established patients only
- Restricted to Haematology for MDS
- RNOH:
- UCLH:
- WH:
- Epoetin is available for treatment anaemia of renal disease only
- Pre-filled syringe 2,000 units, 3,000 units, 4,000 units, 6,000 units, 10,000 units ONLY
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
|
Methoxy Polyethylene Glycol-Epoetin Beta
(Mircera®)
|
Restricted
|
Provider notes
- NMUH:
- RFL:
- Restricted to renal team only - for patients who cannot tolerate darbepoetin or established patients only
- RNOH:
- UCLH:
- WH:
|
|
|
|
|
| 09.01.03 |
Iron overload |
|
|
| .... |
| Non Formulary Items |
Epoetin alfa
(Binocrit®)
|
Non Formulary
|
Approved to treat anaemia (and prevent ribavirin dose reduction) in patients treated for hepatitis C virus (October 2013) |
|
|
Epoetin theta
(Eporatio®)
|
Non Formulary
|
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
|
Epoetin zeta
(Retacrit®)
|
Non Formulary
|
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
|
| |
Key |
|
Traffic Light Status Information
| Status |
Description |
|
Medicines that should be initiated by a specialist. Prescribing can be transferred to primary care once the patient has been stabilised.
Shared care: For drugs with regular, ongoing need for monitoring and/or assessment of efficacy or toxicity. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the North Central London JFC.
Fact sheet: For drugs with some concerns surrounding safety or efficacy but do not require regular monitoring and/or monitoring of effectiveness/toxicity. |
|
Medicines which should normally be prescribed by specialists only (hospital only).
For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.
See link for the complete NCL Red List https://www.ncl-mon.nhs.uk/wp-content/uploads/2017/08/ncl_red_list.pdf |
|
Medicines not recommended for routine use in primary or secondary care.
Medicines, which the North Central London JFC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data. |
|
|
|
